Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model : A Proof-of-Concept Study
Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of personalized medicine - 13(2023), 5 vom: 20. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Turner, Michael A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fluorescent antibody |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jpm13050857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357432525 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357432525 | ||
| 003 | DE-627 | ||
| 005 | 20231226072559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jpm13050857 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357432525 | ||
| 035 | |a (NLM)37241027 | ||
| 035 | |a (PII)857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Turner, Michael A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model |b A Proof-of-Concept Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a fluorescent antibody | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a liver metastasis | |
| 650 | 4 | |a mucin | |
| 650 | 4 | |a pancreatic cancer | |
| 650 | 4 | |a selective targeting | |
| 700 | 1 | |a Cox, Kristin E |e verfasserin |4 aut | |
| 700 | 1 | |a Neel, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Amirfakhri, Siamak |e verfasserin |4 aut | |
| 700 | 1 | |a Nishino, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Clary, Bryan M |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Mojgan |e verfasserin |4 aut | |
| 700 | 1 | |a Natarajan, Gopalakrishnan |e verfasserin |4 aut | |
| 700 | 1 | |a Mallya, Kavita |e verfasserin |4 aut | |
| 700 | 1 | |a Mohs, Aaron M |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffman, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Batra, Surinder K |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvet, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of personalized medicine |d 2011 |g 13(2023), 5 vom: 20. Mai |w (DE-627)NLM228113881 |x 2075-4426 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:5 |g day:20 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jpm13050857 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 5 |b 20 |c 05 | ||